nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ALB—systemic lupus erythematosus	0.25	1	CbGaD
Canagliflozin—UGT1A9—Mycophenolate mofetil—systemic lupus erythematosus	0.112	0.197	CbGbCtD
Canagliflozin—ABCC2—Mycophenolate mofetil—systemic lupus erythematosus	0.0556	0.0983	CbGbCtD
Canagliflozin—ABCC2—Cyclosporine—systemic lupus erythematosus	0.0421	0.0745	CbGbCtD
Canagliflozin—ALB—Mycophenolate mofetil—systemic lupus erythematosus	0.0346	0.0612	CbGbCtD
Canagliflozin—ABCC2—Dexamethasone—systemic lupus erythematosus	0.0277	0.049	CbGbCtD
Canagliflozin—ALB—Prednisone—systemic lupus erythematosus	0.0277	0.049	CbGbCtD
Canagliflozin—ABCB1—Methylprednisolone—systemic lupus erythematosus	0.0239	0.0423	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—systemic lupus erythematosus	0.0223	0.0394	CbGbCtD
Canagliflozin—SLC5A2—urine—systemic lupus erythematosus	0.0183	0.268	CbGeAlD
Canagliflozin—ABCB1—Mycophenolate mofetil—systemic lupus erythematosus	0.0181	0.032	CbGbCtD
Canagliflozin—ABCB1—Betamethasone—systemic lupus erythematosus	0.0155	0.0275	CbGbCtD
Canagliflozin—ABCB1—Prednisolone—systemic lupus erythematosus	0.0153	0.0271	CbGbCtD
Canagliflozin—ABCB1—Hydrocortisone—systemic lupus erythematosus	0.0145	0.0257	CbGbCtD
Canagliflozin—ABCB1—Prednisone—systemic lupus erythematosus	0.0145	0.0256	CbGbCtD
Canagliflozin—CYP3A4—Methylprednisolone—systemic lupus erythematosus	0.0143	0.0253	CbGbCtD
Canagliflozin—ALB—Methotrexate—systemic lupus erythematosus	0.0139	0.0246	CbGbCtD
Canagliflozin—ABCB1—Cyclosporine—systemic lupus erythematosus	0.0137	0.0243	CbGbCtD
Canagliflozin—CYP3A4—Dapsone—systemic lupus erythematosus	0.0125	0.0221	CbGbCtD
Canagliflozin—CYP3A4—Mycophenolate mofetil—systemic lupus erythematosus	0.0109	0.0192	CbGbCtD
Canagliflozin—CYP3A4—Triamcinolone—systemic lupus erythematosus	0.0109	0.0192	CbGbCtD
Canagliflozin—SLC5A2—blood plasma—systemic lupus erythematosus	0.00955	0.14	CbGeAlD
Canagliflozin—CYP3A4—Betamethasone—systemic lupus erythematosus	0.00931	0.0165	CbGbCtD
Canagliflozin—CYP3A4—Prednisolone—systemic lupus erythematosus	0.00919	0.0162	CbGbCtD
Canagliflozin—ABCB1—Dexamethasone—systemic lupus erythematosus	0.00904	0.016	CbGbCtD
Canagliflozin—CYP3A4—Hydrocortisone—systemic lupus erythematosus	0.00871	0.0154	CbGbCtD
Canagliflozin—CYP3A4—Prednisone—systemic lupus erythematosus	0.00868	0.0153	CbGbCtD
Canagliflozin—CYP3A4—Cyclosporine—systemic lupus erythematosus	0.00823	0.0145	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—systemic lupus erythematosus	0.00727	0.0128	CbGbCtD
Canagliflozin—CYP3A4—Dexamethasone—systemic lupus erythematosus	0.00542	0.00958	CbGbCtD
Canagliflozin—SLC5A2—nephron tubule—systemic lupus erythematosus	0.00493	0.0722	CbGeAlD
Canagliflozin—SLC5A2—kidney—systemic lupus erythematosus	0.00433	0.0635	CbGeAlD
Canagliflozin—SLC5A2—cortex of kidney—systemic lupus erythematosus	0.00422	0.0618	CbGeAlD
Canagliflozin—SLC5A1—nephron tubule—systemic lupus erythematosus	0.00373	0.0547	CbGeAlD
Canagliflozin—SLC5A1—kidney—systemic lupus erythematosus	0.00328	0.0481	CbGeAlD
Canagliflozin—SLC5A1—lung—systemic lupus erythematosus	0.00232	0.0341	CbGeAlD
Canagliflozin—UGT2B4—lung—systemic lupus erythematosus	0.00214	0.0314	CbGeAlD
Canagliflozin—UGT1A9—kidney—systemic lupus erythematosus	0.00207	0.0303	CbGeAlD
Canagliflozin—CYP3A4—urine—systemic lupus erythematosus	0.00192	0.0281	CbGeAlD
Canagliflozin—ABCC2—nephron tubule—systemic lupus erythematosus	0.00102	0.0149	CbGeAlD
Canagliflozin—CYP3A4—blood plasma—systemic lupus erythematosus	0.001	0.0147	CbGeAlD
Canagliflozin—ABCC2—kidney—systemic lupus erythematosus	0.000893	0.0131	CbGeAlD
Canagliflozin—ABCC2—cortex of kidney—systemic lupus erythematosus	0.00087	0.0127	CbGeAlD
Canagliflozin—ORM1—bone marrow—systemic lupus erythematosus	0.00085	0.0125	CbGeAlD
Canagliflozin—ORM1—lung—systemic lupus erythematosus	0.00077	0.0113	CbGeAlD
Canagliflozin—ABCC2—tendon—systemic lupus erythematosus	0.000721	0.0106	CbGeAlD
Canagliflozin—ORM1—nervous system—systemic lupus erythematosus	0.000713	0.0105	CbGeAlD
Canagliflozin—ABCB1—blood plasma—systemic lupus erythematosus	0.000708	0.0104	CbGeAlD
Canagliflozin—ORM1—central nervous system—systemic lupus erythematosus	0.000686	0.0101	CbGeAlD
Canagliflozin—CYP3A4—kidney—systemic lupus erythematosus	0.000454	0.00665	CbGeAlD
Canagliflozin—ABCB1—nephron tubule—systemic lupus erythematosus	0.000365	0.00536	CbGeAlD
Canagliflozin—ABCB1—kidney—systemic lupus erythematosus	0.000321	0.00471	CbGeAlD
Canagliflozin—ABCB1—cortex of kidney—systemic lupus erythematosus	0.000313	0.00458	CbGeAlD
Canagliflozin—CYP3A4—nervous system—systemic lupus erythematosus	0.000298	0.00436	CbGeAlD
Canagliflozin—CYP3A4—central nervous system—systemic lupus erythematosus	0.000287	0.0042	CbGeAlD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic lupus erythematosus	0.000282	0.00284	CcSEcCtD
Canagliflozin—Skin disorder—Azathioprine—systemic lupus erythematosus	0.00028	0.00282	CcSEcCtD
Canagliflozin—Dry mouth—Leflunomide—systemic lupus erythematosus	0.000278	0.00279	CcSEcCtD
Canagliflozin—ABCB1—lymphoid tissue—systemic lupus erythematosus	0.000276	0.00404	CbGeAlD
Canagliflozin—Diabetes mellitus—Methotrexate—systemic lupus erythematosus	0.000272	0.00273	CcSEcCtD
Canagliflozin—Infection—Leflunomide—systemic lupus erythematosus	0.000271	0.00272	CcSEcCtD
Canagliflozin—Hypotension—Azathioprine—systemic lupus erythematosus	0.00027	0.00271	CcSEcCtD
Canagliflozin—Photosensitivity—Methotrexate—systemic lupus erythematosus	0.000269	0.00271	CcSEcCtD
Canagliflozin—Polyuria—Methotrexate—systemic lupus erythematosus	0.000269	0.00271	CcSEcCtD
Canagliflozin—Angiopathy—Cyclosporine—systemic lupus erythematosus	0.000269	0.0027	CcSEcCtD
Canagliflozin—Nervous system disorder—Leflunomide—systemic lupus erythematosus	0.000267	0.00268	CcSEcCtD
Canagliflozin—Skin disorder—Leflunomide—systemic lupus erythematosus	0.000265	0.00266	CcSEcCtD
Canagliflozin—Angiopathy—Mycophenolate mofetil—systemic lupus erythematosus	0.000262	0.00263	CcSEcCtD
Canagliflozin—Malnutrition—Cyclosporine—systemic lupus erythematosus	0.000258	0.00259	CcSEcCtD
Canagliflozin—Renal failure acute—Methotrexate—systemic lupus erythematosus	0.000256	0.00257	CcSEcCtD
Canagliflozin—Hypotension—Leflunomide—systemic lupus erythematosus	0.000255	0.00256	CcSEcCtD
Canagliflozin—Malnutrition—Mycophenolate mofetil—systemic lupus erythematosus	0.000251	0.00253	CcSEcCtD
Canagliflozin—ABCB1—bone marrow—systemic lupus erythematosus	0.000251	0.00368	CbGeAlD
Canagliflozin—Gastrointestinal disorder—Azathioprine—systemic lupus erythematosus	0.000249	0.0025	CcSEcCtD
Canagliflozin—Pancreatitis—Prednisone—systemic lupus erythematosus	0.00024	0.00241	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Azathioprine—systemic lupus erythematosus	0.000236	0.00237	CcSEcCtD
Canagliflozin—Angioedema—Cyclosporine—systemic lupus erythematosus	0.000236	0.00237	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Leflunomide—systemic lupus erythematosus	0.000235	0.00236	CcSEcCtD
Canagliflozin—Fatigue—Leflunomide—systemic lupus erythematosus	0.000235	0.00236	CcSEcCtD
Canagliflozin—Erythema—Prednisolone—systemic lupus erythematosus	0.000235	0.00236	CcSEcCtD
Canagliflozin—Constipation—Leflunomide—systemic lupus erythematosus	0.000233	0.00234	CcSEcCtD
Canagliflozin—Angioedema—Mycophenolate mofetil—systemic lupus erythematosus	0.00023	0.00231	CcSEcCtD
Canagliflozin—Erythema—Hydrocortisone—systemic lupus erythematosus	0.000229	0.0023	CcSEcCtD
Canagliflozin—Malnutrition—Hydrocortisone—systemic lupus erythematosus	0.000229	0.0023	CcSEcCtD
Canagliflozin—Abdominal pain—Azathioprine—systemic lupus erythematosus	0.000228	0.00229	CcSEcCtD
Canagliflozin—ABCB1—lung—systemic lupus erythematosus	0.000227	0.00333	CbGeAlD
Canagliflozin—Syncope—Mycophenolate mofetil—systemic lupus erythematosus	0.000225	0.00226	CcSEcCtD
Canagliflozin—Angiopathy—Methylprednisolone—systemic lupus erythematosus	0.000224	0.00225	CcSEcCtD
Canagliflozin—Convulsion—Cyclosporine—systemic lupus erythematosus	0.000223	0.00224	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Leflunomide—systemic lupus erythematosus	0.000223	0.00224	CcSEcCtD
Canagliflozin—Loss of consciousness—Mycophenolate mofetil—systemic lupus erythematosus	0.000221	0.00222	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—systemic lupus erythematosus	0.000218	0.00219	CcSEcCtD
Canagliflozin—Convulsion—Mycophenolate mofetil—systemic lupus erythematosus	0.000218	0.00219	CcSEcCtD
Canagliflozin—Urticaria—Leflunomide—systemic lupus erythematosus	0.000217	0.00217	CcSEcCtD
Canagliflozin—Erythema—Triamcinolone—systemic lupus erythematosus	0.000216	0.00217	CcSEcCtD
Canagliflozin—Abdominal pain—Leflunomide—systemic lupus erythematosus	0.000215	0.00216	CcSEcCtD
Canagliflozin—Erythema—Methylprednisolone—systemic lupus erythematosus	0.000215	0.00216	CcSEcCtD
Canagliflozin—Malnutrition—Methylprednisolone—systemic lupus erythematosus	0.000215	0.00216	CcSEcCtD
Canagliflozin—Dry mouth—Cyclosporine—systemic lupus erythematosus	0.000215	0.00216	CcSEcCtD
Canagliflozin—Angioedema—Prednisolone—systemic lupus erythematosus	0.000214	0.00215	CcSEcCtD
Canagliflozin—Breast disorder—Methotrexate—systemic lupus erythematosus	0.000214	0.00215	CcSEcCtD
Canagliflozin—Hypersensitivity—Azathioprine—systemic lupus erythematosus	0.000213	0.00214	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic lupus erythematosus	0.000213	0.00214	CcSEcCtD
Canagliflozin—ABCB1—nervous system—systemic lupus erythematosus	0.000211	0.00309	CbGeAlD
Canagliflozin—Syncope—Prednisolone—systemic lupus erythematosus	0.00021	0.00211	CcSEcCtD
Canagliflozin—Dry mouth—Mycophenolate mofetil—systemic lupus erythematosus	0.000209	0.0021	CcSEcCtD
Canagliflozin—Angioedema—Hydrocortisone—systemic lupus erythematosus	0.000209	0.0021	CcSEcCtD
Canagliflozin—Infection—Cyclosporine—systemic lupus erythematosus	0.000209	0.0021	CcSEcCtD
Canagliflozin—Nervous system disorder—Cyclosporine—systemic lupus erythematosus	0.000206	0.00207	CcSEcCtD
Canagliflozin—Loss of consciousness—Prednisolone—systemic lupus erythematosus	0.000206	0.00207	CcSEcCtD
Canagliflozin—Syncope—Hydrocortisone—systemic lupus erythematosus	0.000205	0.00206	CcSEcCtD
Canagliflozin—Skin disorder—Cyclosporine—systemic lupus erythematosus	0.000204	0.00205	CcSEcCtD
Canagliflozin—Angiopathy—Betamethasone—systemic lupus erythematosus	0.000204	0.00205	CcSEcCtD
Canagliflozin—Angiopathy—Dexamethasone—systemic lupus erythematosus	0.000204	0.00205	CcSEcCtD
Canagliflozin—Infection—Mycophenolate mofetil—systemic lupus erythematosus	0.000204	0.00205	CcSEcCtD
Canagliflozin—Convulsion—Prednisolone—systemic lupus erythematosus	0.000203	0.00204	CcSEcCtD
Canagliflozin—ABCB1—central nervous system—systemic lupus erythematosus	0.000203	0.00297	CbGeAlD
Canagliflozin—Shock—Mycophenolate mofetil—systemic lupus erythematosus	0.000202	0.00203	CcSEcCtD
Canagliflozin—Loss of consciousness—Hydrocortisone—systemic lupus erythematosus	0.000201	0.00202	CcSEcCtD
Canagliflozin—Nervous system disorder—Mycophenolate mofetil—systemic lupus erythematosus	0.000201	0.00202	CcSEcCtD
Canagliflozin—Hypersensitivity—Leflunomide—systemic lupus erythematosus	0.000201	0.00202	CcSEcCtD
Canagliflozin—Pancreatitis—Methotrexate—systemic lupus erythematosus	0.0002	0.00201	CcSEcCtD
Canagliflozin—Skin disorder—Mycophenolate mofetil—systemic lupus erythematosus	0.000199	0.002	CcSEcCtD
Canagliflozin—Convulsion—Hydrocortisone—systemic lupus erythematosus	0.000198	0.00199	CcSEcCtD
Canagliflozin—Angioedema—Triamcinolone—systemic lupus erythematosus	0.000197	0.00198	CcSEcCtD
Canagliflozin—Angioedema—Methylprednisolone—systemic lupus erythematosus	0.000197	0.00198	CcSEcCtD
Canagliflozin—Erythema—Betamethasone—systemic lupus erythematosus	0.000196	0.00197	CcSEcCtD
Canagliflozin—Erythema—Dexamethasone—systemic lupus erythematosus	0.000196	0.00197	CcSEcCtD
Canagliflozin—Asthenia—Leflunomide—systemic lupus erythematosus	0.000196	0.00196	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—systemic lupus erythematosus	0.000194	0.00195	CcSEcCtD
Canagliflozin—Syncope—Triamcinolone—systemic lupus erythematosus	0.000193	0.00194	CcSEcCtD
Canagliflozin—Syncope—Methylprednisolone—systemic lupus erythematosus	0.000193	0.00194	CcSEcCtD
Canagliflozin—Pruritus—Leflunomide—systemic lupus erythematosus	0.000193	0.00194	CcSEcCtD
Canagliflozin—Hypotension—Mycophenolate mofetil—systemic lupus erythematosus	0.000192	0.00193	CcSEcCtD
Canagliflozin—Dizziness—Azathioprine—systemic lupus erythematosus	0.000191	0.00192	CcSEcCtD
Canagliflozin—Loss of consciousness—Triamcinolone—systemic lupus erythematosus	0.00019	0.0019	CcSEcCtD
Canagliflozin—Loss of consciousness—Methylprednisolone—systemic lupus erythematosus	0.000189	0.0019	CcSEcCtD
Canagliflozin—Shock—Prednisolone—systemic lupus erythematosus	0.000188	0.00189	CcSEcCtD
Canagliflozin—Convulsion—Triamcinolone—systemic lupus erythematosus	0.000187	0.00188	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Methotrexate—systemic lupus erythematosus	0.000187	0.00187	CcSEcCtD
Canagliflozin—Convulsion—Methylprednisolone—systemic lupus erythematosus	0.000186	0.00187	CcSEcCtD
Canagliflozin—Infection—Hydrocortisone—systemic lupus erythematosus	0.000186	0.00187	CcSEcCtD
Canagliflozin—Shock—Hydrocortisone—systemic lupus erythematosus	0.000184	0.00185	CcSEcCtD
Canagliflozin—Nervous system disorder—Hydrocortisone—systemic lupus erythematosus	0.000183	0.00184	CcSEcCtD
Canagliflozin—Rash—Azathioprine—systemic lupus erythematosus	0.000182	0.00183	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—systemic lupus erythematosus	0.000182	0.00183	CcSEcCtD
Canagliflozin—Dermatitis—Azathioprine—systemic lupus erythematosus	0.000182	0.00183	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Cyclosporine—systemic lupus erythematosus	0.000182	0.00182	CcSEcCtD
Canagliflozin—Skin disorder—Hydrocortisone—systemic lupus erythematosus	0.000182	0.00182	CcSEcCtD
Canagliflozin—Fatigue—Cyclosporine—systemic lupus erythematosus	0.000181	0.00182	CcSEcCtD
Canagliflozin—Dizziness—Leflunomide—systemic lupus erythematosus	0.00018	0.00181	CcSEcCtD
Canagliflozin—Constipation—Cyclosporine—systemic lupus erythematosus	0.00018	0.00181	CcSEcCtD
Canagliflozin—Dry mouth—Triamcinolone—systemic lupus erythematosus	0.00018	0.0018	CcSEcCtD
Canagliflozin—Angioedema—Dexamethasone—systemic lupus erythematosus	0.000179	0.0018	CcSEcCtD
Canagliflozin—Angioedema—Betamethasone—systemic lupus erythematosus	0.000179	0.0018	CcSEcCtD
Canagliflozin—Angiopathy—Prednisone—systemic lupus erythematosus	0.000178	0.00178	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Mycophenolate mofetil—systemic lupus erythematosus	0.000177	0.00178	CcSEcCtD
Canagliflozin—Syncope—Dexamethasone—systemic lupus erythematosus	0.000176	0.00176	CcSEcCtD
Canagliflozin—Syncope—Betamethasone—systemic lupus erythematosus	0.000176	0.00176	CcSEcCtD
Canagliflozin—Constipation—Mycophenolate mofetil—systemic lupus erythematosus	0.000175	0.00176	CcSEcCtD
Canagliflozin—Infection—Triamcinolone—systemic lupus erythematosus	0.000175	0.00176	CcSEcCtD
Canagliflozin—Hypotension—Hydrocortisone—systemic lupus erythematosus	0.000175	0.00175	CcSEcCtD
Canagliflozin—Infection—Methylprednisolone—systemic lupus erythematosus	0.000174	0.00175	CcSEcCtD
Canagliflozin—Shock—Triamcinolone—systemic lupus erythematosus	0.000173	0.00174	CcSEcCtD
Canagliflozin—Shock—Methylprednisolone—systemic lupus erythematosus	0.000173	0.00174	CcSEcCtD
Canagliflozin—Nervous system disorder—Methylprednisolone—systemic lupus erythematosus	0.000172	0.00173	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Cyclosporine—systemic lupus erythematosus	0.000172	0.00173	CcSEcCtD
Canagliflozin—Loss of consciousness—Dexamethasone—systemic lupus erythematosus	0.000172	0.00173	CcSEcCtD
Canagliflozin—Loss of consciousness—Betamethasone—systemic lupus erythematosus	0.000172	0.00173	CcSEcCtD
Canagliflozin—Rash—Leflunomide—systemic lupus erythematosus	0.000172	0.00173	CcSEcCtD
Canagliflozin—Dermatitis—Leflunomide—systemic lupus erythematosus	0.000172	0.00172	CcSEcCtD
Canagliflozin—Nausea—Azathioprine—systemic lupus erythematosus	0.000171	0.00172	CcSEcCtD
Canagliflozin—Skin disorder—Methylprednisolone—systemic lupus erythematosus	0.000171	0.00171	CcSEcCtD
Canagliflozin—Malnutrition—Prednisone—systemic lupus erythematosus	0.00017	0.00171	CcSEcCtD
Canagliflozin—Erythema—Prednisone—systemic lupus erythematosus	0.00017	0.00171	CcSEcCtD
Canagliflozin—Convulsion—Dexamethasone—systemic lupus erythematosus	0.00017	0.0017	CcSEcCtD
Canagliflozin—Convulsion—Betamethasone—systemic lupus erythematosus	0.00017	0.0017	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Mycophenolate mofetil—systemic lupus erythematosus	0.000168	0.00169	CcSEcCtD
Canagliflozin—Urticaria—Cyclosporine—systemic lupus erythematosus	0.000167	0.00168	CcSEcCtD
Canagliflozin—Abdominal pain—Cyclosporine—systemic lupus erythematosus	0.000166	0.00167	CcSEcCtD
Canagliflozin—Hypotension—Methylprednisolone—systemic lupus erythematosus	0.000164	0.00165	CcSEcCtD
Canagliflozin—Urticaria—Mycophenolate mofetil—systemic lupus erythematosus	0.000163	0.00164	CcSEcCtD
Canagliflozin—Abdominal pain—Mycophenolate mofetil—systemic lupus erythematosus	0.000162	0.00163	CcSEcCtD
Canagliflozin—Nausea—Leflunomide—systemic lupus erythematosus	0.000162	0.00163	CcSEcCtD
Canagliflozin—Urinary tract disorder—Methotrexate—systemic lupus erythematosus	0.000162	0.00162	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	0.000161	0.00162	CcSEcCtD
Canagliflozin—Fatigue—Hydrocortisone—systemic lupus erythematosus	0.000161	0.00162	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—systemic lupus erythematosus	0.00016	0.00161	CcSEcCtD
Canagliflozin—Infection—Dexamethasone—systemic lupus erythematosus	0.000159	0.00159	CcSEcCtD
Canagliflozin—Infection—Betamethasone—systemic lupus erythematosus	0.000159	0.00159	CcSEcCtD
Canagliflozin—Shock—Betamethasone—systemic lupus erythematosus	0.000157	0.00158	CcSEcCtD
Canagliflozin—Shock—Dexamethasone—systemic lupus erythematosus	0.000157	0.00158	CcSEcCtD
Canagliflozin—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	0.000157	0.00157	CcSEcCtD
Canagliflozin—Nervous system disorder—Betamethasone—systemic lupus erythematosus	0.000157	0.00157	CcSEcCtD
Canagliflozin—Angioedema—Prednisone—systemic lupus erythematosus	0.000156	0.00156	CcSEcCtD
Canagliflozin—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	0.000155	0.00156	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	0.000153	0.00154	CcSEcCtD
Canagliflozin—Syncope—Prednisone—systemic lupus erythematosus	0.000153	0.00154	CcSEcCtD
Canagliflozin—Urticaria—Prednisolone—systemic lupus erythematosus	0.000152	0.00153	CcSEcCtD
Canagliflozin—Fatigue—Triamcinolone—systemic lupus erythematosus	0.000152	0.00152	CcSEcCtD
Canagliflozin—Fatigue—Methylprednisolone—systemic lupus erythematosus	0.000151	0.00152	CcSEcCtD
Canagliflozin—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	0.000151	0.00152	CcSEcCtD
Canagliflozin—Asthenia—Cyclosporine—systemic lupus erythematosus	0.000151	0.00152	CcSEcCtD
Canagliflozin—Loss of consciousness—Prednisone—systemic lupus erythematosus	0.00015	0.0015	CcSEcCtD
Canagliflozin—Hypotension—Betamethasone—systemic lupus erythematosus	0.000149	0.0015	CcSEcCtD
Canagliflozin—Hypotension—Dexamethasone—systemic lupus erythematosus	0.000149	0.0015	CcSEcCtD
Canagliflozin—Pruritus—Cyclosporine—systemic lupus erythematosus	0.000149	0.00149	CcSEcCtD
Canagliflozin—Urticaria—Hydrocortisone—systemic lupus erythematosus	0.000149	0.00149	CcSEcCtD
Canagliflozin—Angiopathy—Methotrexate—systemic lupus erythematosus	0.000148	0.00149	CcSEcCtD
Canagliflozin—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	0.000148	0.00148	CcSEcCtD
Canagliflozin—Convulsion—Prednisone—systemic lupus erythematosus	0.000148	0.00148	CcSEcCtD
Canagliflozin—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	0.000147	0.00148	CcSEcCtD
Canagliflozin—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	0.000145	0.00146	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	0.000144	0.00145	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	0.000144	0.00144	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—systemic lupus erythematosus	0.000142	0.00143	CcSEcCtD
Canagliflozin—Erythema—Methotrexate—systemic lupus erythematosus	0.000142	0.00143	CcSEcCtD
Canagliflozin—Hypersensitivity—Prednisolone—systemic lupus erythematosus	0.000141	0.00142	CcSEcCtD
Canagliflozin—Urticaria—Triamcinolone—systemic lupus erythematosus	0.00014	0.0014	CcSEcCtD
Canagliflozin—Urticaria—Methylprednisolone—systemic lupus erythematosus	0.00014	0.0014	CcSEcCtD
Canagliflozin—Dizziness—Cyclosporine—systemic lupus erythematosus	0.000139	0.0014	CcSEcCtD
Canagliflozin—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	0.000139	0.00139	CcSEcCtD
Canagliflozin—Infection—Prednisone—systemic lupus erythematosus	0.000138	0.00139	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	0.000138	0.00138	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	0.000138	0.00138	CcSEcCtD
Canagliflozin—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	0.000138	0.00138	CcSEcCtD
Canagliflozin—Fatigue—Dexamethasone—systemic lupus erythematosus	0.000138	0.00138	CcSEcCtD
Canagliflozin—Fatigue—Betamethasone—systemic lupus erythematosus	0.000138	0.00138	CcSEcCtD
Canagliflozin—Shock—Prednisone—systemic lupus erythematosus	0.000137	0.00137	CcSEcCtD
Canagliflozin—Nervous system disorder—Prednisone—systemic lupus erythematosus	0.000136	0.00137	CcSEcCtD
Canagliflozin—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	0.000136	0.00136	CcSEcCtD
Canagliflozin—Skin disorder—Prednisone—systemic lupus erythematosus	0.000135	0.00136	CcSEcCtD
Canagliflozin—Asthenia—Hydrocortisone—systemic lupus erythematosus	0.000134	0.00135	CcSEcCtD
Canagliflozin—Rash—Cyclosporine—systemic lupus erythematosus	0.000133	0.00133	CcSEcCtD
Canagliflozin—Dermatitis—Cyclosporine—systemic lupus erythematosus	0.000133	0.00133	CcSEcCtD
Canagliflozin—Pruritus—Hydrocortisone—systemic lupus erythematosus	0.000132	0.00133	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	0.000131	0.00131	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	0.000131	0.00131	CcSEcCtD
Canagliflozin—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	0.00013	0.0013	CcSEcCtD
Canagliflozin—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	0.000129	0.0013	CcSEcCtD
Canagliflozin—Rash—Mycophenolate mofetil—systemic lupus erythematosus	0.000129	0.0013	CcSEcCtD
Canagliflozin—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	0.000129	0.0013	CcSEcCtD
Canagliflozin—Urticaria—Betamethasone—systemic lupus erythematosus	0.000127	0.00127	CcSEcCtD
Canagliflozin—Urticaria—Dexamethasone—systemic lupus erythematosus	0.000127	0.00127	CcSEcCtD
Canagliflozin—Dizziness—Prednisolone—systemic lupus erythematosus	0.000127	0.00127	CcSEcCtD
Canagliflozin—Asthenia—Triamcinolone—systemic lupus erythematosus	0.000126	0.00127	CcSEcCtD
Canagliflozin—Abdominal pain—Dexamethasone—systemic lupus erythematosus	0.000126	0.00127	CcSEcCtD
Canagliflozin—Abdominal pain—Betamethasone—systemic lupus erythematosus	0.000126	0.00127	CcSEcCtD
Canagliflozin—Asthenia—Methylprednisolone—systemic lupus erythematosus	0.000126	0.00127	CcSEcCtD
Canagliflozin—Nausea—Cyclosporine—systemic lupus erythematosus	0.000125	0.00125	CcSEcCtD
Canagliflozin—Pruritus—Triamcinolone—systemic lupus erythematosus	0.000125	0.00125	CcSEcCtD
Canagliflozin—Pruritus—Methylprednisolone—systemic lupus erythematosus	0.000124	0.00125	CcSEcCtD
Canagliflozin—Dizziness—Hydrocortisone—systemic lupus erythematosus	0.000124	0.00124	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—systemic lupus erythematosus	0.000123	0.00124	CcSEcCtD
Canagliflozin—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	0.000122	0.00122	CcSEcCtD
Canagliflozin—Rash—Prednisolone—systemic lupus erythematosus	0.000121	0.00121	CcSEcCtD
Canagliflozin—Dermatitis—Prednisolone—systemic lupus erythematosus	0.000121	0.00121	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	0.00012	0.00121	CcSEcCtD
Canagliflozin—Fatigue—Prednisone—systemic lupus erythematosus	0.00012	0.0012	CcSEcCtD
Canagliflozin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	0.00012	0.00741	CbGpPWpGaD
Canagliflozin—Constipation—Prednisone—systemic lupus erythematosus	0.000119	0.00119	CcSEcCtD
Canagliflozin—Rash—Hydrocortisone—systemic lupus erythematosus	0.000118	0.00118	CcSEcCtD
Canagliflozin—Dermatitis—Hydrocortisone—systemic lupus erythematosus	0.000118	0.00118	CcSEcCtD
Canagliflozin—Dizziness—Triamcinolone—systemic lupus erythematosus	0.000116	0.00117	CcSEcCtD
Canagliflozin—Dizziness—Methylprednisolone—systemic lupus erythematosus	0.000116	0.00117	CcSEcCtD
Canagliflozin—Infection—Methotrexate—systemic lupus erythematosus	0.000115	0.00116	CcSEcCtD
Canagliflozin—Asthenia—Dexamethasone—systemic lupus erythematosus	0.000115	0.00115	CcSEcCtD
Canagliflozin—Asthenia—Betamethasone—systemic lupus erythematosus	0.000115	0.00115	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—systemic lupus erythematosus	0.000114	0.00114	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	0.000114	0.00114	CcSEcCtD
Canagliflozin—Nausea—Prednisolone—systemic lupus erythematosus	0.000114	0.00114	CcSEcCtD
Canagliflozin—Pruritus—Betamethasone—systemic lupus erythematosus	0.000113	0.00113	CcSEcCtD
Canagliflozin—Pruritus—Dexamethasone—systemic lupus erythematosus	0.000113	0.00113	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—systemic lupus erythematosus	0.000113	0.00113	CcSEcCtD
Canagliflozin—Nausea—Hydrocortisone—systemic lupus erythematosus	0.000111	0.00112	CcSEcCtD
Canagliflozin—Rash—Triamcinolone—systemic lupus erythematosus	0.000111	0.00111	CcSEcCtD
Canagliflozin—Dermatitis—Triamcinolone—systemic lupus erythematosus	0.000111	0.00111	CcSEcCtD
Canagliflozin—Rash—Methylprednisolone—systemic lupus erythematosus	0.000111	0.00111	CcSEcCtD
Canagliflozin—Dermatitis—Methylprednisolone—systemic lupus erythematosus	0.000111	0.00111	CcSEcCtD
Canagliflozin—Urticaria—Prednisone—systemic lupus erythematosus	0.000111	0.00111	CcSEcCtD
Canagliflozin—Abdominal pain—Prednisone—systemic lupus erythematosus	0.00011	0.0011	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—systemic lupus erythematosus	0.000109	0.00109	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—C4A—systemic lupus erythematosus	0.000107	0.00662	CbGpPWpGaD
Canagliflozin—Dizziness—Betamethasone—systemic lupus erythematosus	0.000106	0.00106	CcSEcCtD
Canagliflozin—Dizziness—Dexamethasone—systemic lupus erythematosus	0.000106	0.00106	CcSEcCtD
Canagliflozin—Nausea—Triamcinolone—systemic lupus erythematosus	0.000105	0.00105	CcSEcCtD
Canagliflozin—Nausea—Methylprednisolone—systemic lupus erythematosus	0.000104	0.00105	CcSEcCtD
Canagliflozin—Hypersensitivity—Prednisone—systemic lupus erythematosus	0.000102	0.00103	CcSEcCtD
Canagliflozin—Rash—Betamethasone—systemic lupus erythematosus	0.000101	0.00101	CcSEcCtD
Canagliflozin—Rash—Dexamethasone—systemic lupus erythematosus	0.000101	0.00101	CcSEcCtD
Canagliflozin—Dermatitis—Dexamethasone—systemic lupus erythematosus	0.000101	0.00101	CcSEcCtD
Canagliflozin—Dermatitis—Betamethasone—systemic lupus erythematosus	0.000101	0.00101	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	0.0001	0.00101	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—systemic lupus erythematosus	0.0001	0.00101	CcSEcCtD
Canagliflozin—Asthenia—Prednisone—systemic lupus erythematosus	9.98e-05	0.001	CcSEcCtD
Canagliflozin—Pruritus—Prednisone—systemic lupus erythematosus	9.84e-05	0.000988	CcSEcCtD
Canagliflozin—ALB—Bile acid and bile salt metabolism—RXRA—systemic lupus erythematosus	9.73e-05	0.00602	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—LYN—systemic lupus erythematosus	9.62e-05	0.00595	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	9.51e-05	0.000955	CcSEcCtD
Canagliflozin—Nausea—Betamethasone—systemic lupus erythematosus	9.49e-05	0.000953	CcSEcCtD
Canagliflozin—Nausea—Dexamethasone—systemic lupus erythematosus	9.49e-05	0.000953	CcSEcCtD
Canagliflozin—UGT1A9—Biological oxidations—NAT2—systemic lupus erythematosus	9.49e-05	0.00587	CbGpPWpGaD
Canagliflozin—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	9.37e-05	0.00579	CbGpPWpGaD
Canagliflozin—UGT1A9—Metapathway biotransformation—NAT2—systemic lupus erythematosus	9.36e-05	0.00579	CbGpPWpGaD
Canagliflozin—Urticaria—Methotrexate—systemic lupus erythematosus	9.24e-05	0.000928	CcSEcCtD
Canagliflozin—Dizziness—Prednisone—systemic lupus erythematosus	9.2e-05	0.000924	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—systemic lupus erythematosus	9.19e-05	0.000923	CcSEcCtD
Canagliflozin—ALB—Platelet degranulation—CLU—systemic lupus erythematosus	9.16e-05	0.00567	CbGpPWpGaD
Canagliflozin—Rash—Prednisone—systemic lupus erythematosus	8.77e-05	0.000881	CcSEcCtD
Canagliflozin—Dermatitis—Prednisone—systemic lupus erythematosus	8.76e-05	0.00088	CcSEcCtD
Canagliflozin—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—systemic lupus erythematosus	8.76e-05	0.00542	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—CLU—systemic lupus erythematosus	8.73e-05	0.0054	CbGpPWpGaD
Canagliflozin—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—systemic lupus erythematosus	8.67e-05	0.00536	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Methotrexate—systemic lupus erythematosus	8.56e-05	0.00086	CcSEcCtD
Canagliflozin—SLC5A1—Disease—XRCC6—systemic lupus erythematosus	8.41e-05	0.0052	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—XRCC6—systemic lupus erythematosus	8.41e-05	0.0052	CbGpPWpGaD
Canagliflozin—Asthenia—Methotrexate—systemic lupus erythematosus	8.34e-05	0.000838	CcSEcCtD
Canagliflozin—Nausea—Prednisone—systemic lupus erythematosus	8.26e-05	0.00083	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—systemic lupus erythematosus	8.22e-05	0.000826	CcSEcCtD
Canagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	8.08e-05	0.005	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—GADD45A—systemic lupus erythematosus	8.06e-05	0.00499	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—systemic lupus erythematosus	7.91e-05	0.0049	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC15A4—systemic lupus erythematosus	7.86e-05	0.00486	CbGpPWpGaD
Canagliflozin—Dizziness—Methotrexate—systemic lupus erythematosus	7.69e-05	0.000772	CcSEcCtD
Canagliflozin—SLC5A2—NRF2 pathway—TGFB1—systemic lupus erythematosus	7.62e-05	0.00471	CbGpPWpGaD
Canagliflozin—SLC5A1—NRF2 pathway—TGFB1—systemic lupus erythematosus	7.62e-05	0.00471	CbGpPWpGaD
Canagliflozin—UGT1A9—PPARA activates gene expression—RXRA—systemic lupus erythematosus	7.6e-05	0.0047	CbGpPWpGaD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—ALB—systemic lupus erythematosus	7.59e-05	0.0047	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—ALB—systemic lupus erythematosus	7.59e-05	0.0047	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—FOXP3—systemic lupus erythematosus	7.48e-05	0.00463	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC15A4—systemic lupus erythematosus	7.44e-05	0.0046	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—systemic lupus erythematosus	7.44e-05	0.0046	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—ETS1—systemic lupus erythematosus	7.44e-05	0.0046	CbGpPWpGaD
Canagliflozin—Rash—Methotrexate—systemic lupus erythematosus	7.33e-05	0.000736	CcSEcCtD
Canagliflozin—Dermatitis—Methotrexate—systemic lupus erythematosus	7.32e-05	0.000735	CcSEcCtD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CDKN1B—systemic lupus erythematosus	7.19e-05	0.00445	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—systemic lupus erythematosus	7.03e-05	0.00435	CbGpPWpGaD
Canagliflozin—Nausea—Methotrexate—systemic lupus erythematosus	6.91e-05	0.000694	CcSEcCtD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	6.8e-05	0.0042	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	6.8e-05	0.0042	CbGpPWpGaD
Canagliflozin—ALB—FOXA2 and FOXA3 transcription factor networks—NR3C1—systemic lupus erythematosus	6.76e-05	0.00418	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—systemic lupus erythematosus	6.31e-05	0.0039	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HIST2H2AC—systemic lupus erythematosus	6.2e-05	0.00384	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HIST2H2AC—systemic lupus erythematosus	6.2e-05	0.00384	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—CXCL12—systemic lupus erythematosus	6.1e-05	0.00378	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—RXRA—systemic lupus erythematosus	6.06e-05	0.00375	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CSK—systemic lupus erythematosus	6.04e-05	0.00374	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CSK—systemic lupus erythematosus	6.04e-05	0.00374	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—RXRA—systemic lupus erythematosus	5.92e-05	0.00366	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL17A—systemic lupus erythematosus	5.89e-05	0.00365	CbGpPWpGaD
Canagliflozin—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	5.77e-05	0.00357	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CD247—systemic lupus erythematosus	5.68e-05	0.00351	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CD247—systemic lupus erythematosus	5.68e-05	0.00351	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—NAT2—systemic lupus erythematosus	5.68e-05	0.00351	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—NAT2—systemic lupus erythematosus	5.68e-05	0.00351	CbGpPWpGaD
Canagliflozin—ALB—FOXA2 and FOXA3 transcription factor networks—F2—systemic lupus erythematosus	5.66e-05	0.0035	CbGpPWpGaD
Canagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	5.63e-05	0.00349	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NCF2—systemic lupus erythematosus	5.53e-05	0.00342	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NCF2—systemic lupus erythematosus	5.53e-05	0.00342	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	5.48e-05	0.00339	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL12B—systemic lupus erythematosus	5.48e-05	0.00339	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—CRP—systemic lupus erythematosus	5.45e-05	0.00337	CbGpPWpGaD
Canagliflozin—UGT1A9—Biological oxidations—RXRA—systemic lupus erythematosus	5.32e-05	0.00329	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CXCL12—systemic lupus erythematosus	5.28e-05	0.00327	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CD40—systemic lupus erythematosus	5.23e-05	0.00323	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CTLA4—systemic lupus erythematosus	5.15e-05	0.00319	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL4—systemic lupus erythematosus	5.13e-05	0.00318	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—systemic lupus erythematosus	5.13e-05	0.00317	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—systemic lupus erythematosus	5.12e-05	0.00317	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—F2—systemic lupus erythematosus	5.03e-05	0.00311	CbGpPWpGaD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	4.98e-05	0.00308	CbGpPWpGaD
Canagliflozin—UGT1A9—PPARA activates gene expression—PPARG—systemic lupus erythematosus	4.8e-05	0.00297	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—systemic lupus erythematosus	4.7e-05	0.00291	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-DQA1—systemic lupus erythematosus	4.53e-05	0.0028	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—CCL2—systemic lupus erythematosus	4.49e-05	0.00278	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—CRP—systemic lupus erythematosus	4.44e-05	0.00275	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—NAT2—systemic lupus erythematosus	4.38e-05	0.00271	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—JUNB—systemic lupus erythematosus	4.34e-05	0.00268	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—JUNB—systemic lupus erythematosus	4.34e-05	0.00268	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-DQB1—systemic lupus erythematosus	4.24e-05	0.00262	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—F2—systemic lupus erythematosus	4.1e-05	0.00253	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—CLU—systemic lupus erythematosus	4.06e-05	0.00251	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL10—systemic lupus erythematosus	4.01e-05	0.00248	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CD40LG—systemic lupus erythematosus	4.01e-05	0.00248	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PRL—systemic lupus erythematosus	4e-05	0.00247	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PRL—systemic lupus erythematosus	4e-05	0.00247	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC15A4—systemic lupus erythematosus	3.99e-05	0.00247	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—P2RY12—systemic lupus erythematosus	3.94e-05	0.00244	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL4—systemic lupus erythematosus	3.9e-05	0.00241	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	3.86e-05	0.00239	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	3.86e-05	0.00239	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IFNG—systemic lupus erythematosus	3.81e-05	0.00236	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—FASLG—systemic lupus erythematosus	3.72e-05	0.0023	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—CCL2—systemic lupus erythematosus	3.65e-05	0.00226	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—CSK—systemic lupus erythematosus	3.62e-05	0.00224	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—FAS—systemic lupus erythematosus	3.59e-05	0.00222	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL2RA—systemic lupus erythematosus	3.57e-05	0.00221	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—C3—systemic lupus erythematosus	3.54e-05	0.00219	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—CRP—systemic lupus erythematosus	3.53e-05	0.00218	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC15A4—systemic lupus erythematosus	3.5e-05	0.00217	CbGpPWpGaD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	3.49e-05	0.00216	CbGpPWpGaD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	3.47e-05	0.00215	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—LYN—systemic lupus erythematosus	3.29e-05	0.00204	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—F2—systemic lupus erythematosus	3.25e-05	0.00201	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—systemic lupus erythematosus	3.24e-05	0.002	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—HLA-DRB1—systemic lupus erythematosus	3.22e-05	0.00199	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—JAK1—systemic lupus erythematosus	3.2e-05	0.00198	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—JAK1—systemic lupus erythematosus	3.2e-05	0.00198	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—RXRA—systemic lupus erythematosus	3.18e-05	0.00197	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—RXRA—systemic lupus erythematosus	3.18e-05	0.00197	CbGpPWpGaD
Canagliflozin—UGT1A9—PPARA activates gene expression—EP300—systemic lupus erythematosus	3.14e-05	0.00194	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—systemic lupus erythematosus	3.13e-05	0.00194	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IFNG—systemic lupus erythematosus	3.1e-05	0.00192	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—systemic lupus erythematosus	3.07e-05	0.0019	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CCR5—systemic lupus erythematosus	3.03e-05	0.00187	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CCR5—systemic lupus erythematosus	3.03e-05	0.00187	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CD80—systemic lupus erythematosus	2.98e-05	0.00184	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—CCL2—systemic lupus erythematosus	2.9e-05	0.00179	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	2.83e-05	0.00175	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL2—systemic lupus erythematosus	2.76e-05	0.00171	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—systemic lupus erythematosus	2.71e-05	0.00168	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—NAT2—systemic lupus erythematosus	2.68e-05	0.00166	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—NAT2—systemic lupus erythematosus	2.64e-05	0.00164	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—systemic lupus erythematosus	2.56e-05	0.00158	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CD80—systemic lupus erythematosus	2.49e-05	0.00154	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CD80—systemic lupus erythematosus	2.49e-05	0.00154	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—RASGRP1—systemic lupus erythematosus	2.47e-05	0.00153	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—TNF—systemic lupus erythematosus	2.47e-05	0.00153	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IFNG—systemic lupus erythematosus	2.47e-05	0.00153	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—RXRA—systemic lupus erythematosus	2.46e-05	0.00152	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—PTGS2—systemic lupus erythematosus	2.36e-05	0.00146	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IFNG—systemic lupus erythematosus	2.36e-05	0.00146	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ITGAX—systemic lupus erythematosus	2.35e-05	0.00145	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—F3—systemic lupus erythematosus	2.32e-05	0.00143	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—systemic lupus erythematosus	2.24e-05	0.00139	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—TGFB1—systemic lupus erythematosus	2.18e-05	0.00135	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—EP300—systemic lupus erythematosus	2.17e-05	0.00134	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—TGFB1—systemic lupus erythematosus	2.12e-05	0.00131	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—systemic lupus erythematosus	2.12e-05	0.00131	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TYK2—systemic lupus erythematosus	2.1e-05	0.0013	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TYK2—systemic lupus erythematosus	2.1e-05	0.0013	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CLU—systemic lupus erythematosus	2.09e-05	0.0013	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL2—systemic lupus erythematosus	2.09e-05	0.00129	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NOS3—systemic lupus erythematosus	2.06e-05	0.00128	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NOS3—systemic lupus erythematosus	2.06e-05	0.00128	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—systemic lupus erythematosus	2.05e-05	0.00127	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	2.04e-05	0.00126	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—P2RY12—systemic lupus erythematosus	2.03e-05	0.00126	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—VEGFA—systemic lupus erythematosus	2.01e-05	0.00124	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PPARG—systemic lupus erythematosus	2.01e-05	0.00124	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PPARG—systemic lupus erythematosus	2.01e-05	0.00124	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TNF—systemic lupus erythematosus	2.01e-05	0.00124	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IL6—systemic lupus erythematosus	1.99e-05	0.00123	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—JAK1—systemic lupus erythematosus	1.92e-05	0.00119	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—systemic lupus erythematosus	1.91e-05	0.00118	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CD4—systemic lupus erythematosus	1.9e-05	0.00118	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CD4—systemic lupus erythematosus	1.9e-05	0.00118	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	1.89e-05	0.00117	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTGS2—systemic lupus erythematosus	1.89e-05	0.00117	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTGS2—systemic lupus erythematosus	1.89e-05	0.00117	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CSK—systemic lupus erythematosus	1.87e-05	0.00116	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SELE—systemic lupus erythematosus	1.87e-05	0.00116	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—TGFB1—systemic lupus erythematosus	1.84e-05	0.00114	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—systemic lupus erythematosus	1.84e-05	0.00114	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ALB—systemic lupus erythematosus	1.81e-05	0.00112	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ALB—systemic lupus erythematosus	1.81e-05	0.00112	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2RA—systemic lupus erythematosus	1.79e-05	0.00111	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CDKN1B—systemic lupus erythematosus	1.79e-05	0.00111	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CDKN1B—systemic lupus erythematosus	1.79e-05	0.00111	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—VEGFA—systemic lupus erythematosus	1.78e-05	0.0011	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—systemic lupus erythematosus	1.77e-05	0.0011	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic lupus erythematosus	1.76e-05	0.00109	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ITGAM—systemic lupus erythematosus	1.76e-05	0.00109	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—NOS3—systemic lupus erythematosus	1.73e-05	0.00107	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—NOS3—systemic lupus erythematosus	1.73e-05	0.00107	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—LYN—systemic lupus erythematosus	1.7e-05	0.00105	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SH2B3—systemic lupus erythematosus	1.66e-05	0.00103	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CDKN1A—systemic lupus erythematosus	1.65e-05	0.00102	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CDKN1A—systemic lupus erythematosus	1.65e-05	0.00102	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TGFB1—systemic lupus erythematosus	1.63e-05	0.00101	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NAT2—systemic lupus erythematosus	1.62e-05	0.001	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL6—systemic lupus erythematosus	1.62e-05	0.001	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—TNF—systemic lupus erythematosus	1.6e-05	0.000987	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTGS2—systemic lupus erythematosus	1.58e-05	0.000978	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTGS2—systemic lupus erythematosus	1.58e-05	0.000978	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EP300—systemic lupus erythematosus	1.57e-05	0.000971	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EP300—systemic lupus erythematosus	1.57e-05	0.000971	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—F2—systemic lupus erythematosus	1.56e-05	0.000963	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PPARG—systemic lupus erythematosus	1.55e-05	0.00096	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TNF—systemic lupus erythematosus	1.52e-05	0.000943	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—RXRA—systemic lupus erythematosus	1.5e-05	0.00093	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ALB—systemic lupus erythematosus	1.4e-05	0.000863	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TGFB1—systemic lupus erythematosus	1.36e-05	0.000844	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TGFB1—systemic lupus erythematosus	1.36e-05	0.000844	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—NOS3—systemic lupus erythematosus	1.33e-05	0.000826	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—EP300—systemic lupus erythematosus	1.31e-05	0.000813	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—EP300—systemic lupus erythematosus	1.31e-05	0.000813	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNA1—systemic lupus erythematosus	1.31e-05	0.000809	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.29e-05	0.000798	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL6—systemic lupus erythematosus	1.29e-05	0.000797	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—RASGRP1—systemic lupus erythematosus	1.27e-05	0.000788	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—systemic lupus erythematosus	1.22e-05	0.000755	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	1.16e-05	0.000717	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—systemic lupus erythematosus	1.11e-05	0.000689	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	1.08e-05	0.000665	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	1.07e-05	0.000661	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—systemic lupus erythematosus	1.06e-05	0.000653	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2—systemic lupus erythematosus	1.05e-05	0.000649	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6—systemic lupus erythematosus	1.03e-05	0.000636	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6—systemic lupus erythematosus	1.03e-05	0.000636	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	1.02e-05	0.000629	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—EP300—systemic lupus erythematosus	1.02e-05	0.000628	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	1.01e-05	0.000627	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—JAK1—systemic lupus erythematosus	9.87e-06	0.000611	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—systemic lupus erythematosus	9.74e-06	0.000603	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—systemic lupus erythematosus	9.27e-06	0.000573	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2RA—systemic lupus erythematosus	9.22e-06	0.00057	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—RXRA—systemic lupus erythematosus	9.09e-06	0.000563	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—systemic lupus erythematosus	8.91e-06	0.000551	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	8.91e-06	0.000551	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—systemic lupus erythematosus	8.78e-06	0.000543	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NAT2—systemic lupus erythematosus	8.49e-06	0.000525	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	8.44e-06	0.000522	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic lupus erythematosus	8.18e-06	0.000506	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic lupus erythematosus	8.06e-06	0.000498	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—F2—systemic lupus erythematosus	8.03e-06	0.000497	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—systemic lupus erythematosus	7.52e-06	0.000465	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NAT2—systemic lupus erythematosus	7.44e-06	0.00046	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	6.75e-06	0.000418	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS3—systemic lupus erythematosus	6.38e-06	0.000395	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARG—systemic lupus erythematosus	5.74e-06	0.000355	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2—systemic lupus erythematosus	5.41e-06	0.000334	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	5.31e-06	0.000329	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALB—systemic lupus erythematosus	5.16e-06	0.000319	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	5.06e-06	0.000313	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NOS3—systemic lupus erythematosus	4.94e-06	0.000306	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—EP300—systemic lupus erythematosus	4.85e-06	0.0003	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—RXRA—systemic lupus erythematosus	4.76e-06	0.000295	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—systemic lupus erythematosus	4.59e-06	0.000284	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NAT2—systemic lupus erythematosus	4.59e-06	0.000284	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—systemic lupus erythematosus	4.52e-06	0.000279	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	4.42e-06	0.000273	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB1—systemic lupus erythematosus	4.22e-06	0.000261	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—RXRA—systemic lupus erythematosus	4.17e-06	0.000258	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—EP300—systemic lupus erythematosus	3.76e-06	0.000232	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARG—systemic lupus erythematosus	3.01e-06	0.000186	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARG—systemic lupus erythematosus	2.63e-06	0.000163	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NOS3—systemic lupus erythematosus	2.59e-06	0.00016	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—RXRA—systemic lupus erythematosus	2.57e-06	0.000159	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALB—systemic lupus erythematosus	2.37e-06	0.000147	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—systemic lupus erythematosus	2.36e-06	0.000146	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NOS3—systemic lupus erythematosus	2.27e-06	0.00014	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—systemic lupus erythematosus	2.07e-06	0.000128	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—EP300—systemic lupus erythematosus	1.97e-06	0.000122	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—EP300—systemic lupus erythematosus	1.72e-06	0.000107	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARG—systemic lupus erythematosus	1.62e-06	0.0001	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALB—systemic lupus erythematosus	1.46e-06	9.03e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NOS3—systemic lupus erythematosus	1.4e-06	8.64e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—systemic lupus erythematosus	1.28e-06	7.9e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—EP300—systemic lupus erythematosus	1.06e-06	6.57e-05	CbGpPWpGaD
